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Abstract
Introduction Circulating tumor cells (CTCs) are detectable in
most cancer patients and they can meet an existing medical
need to monitor cancer patients during a course of treatment
and to help determine recurrent disease. CTCs are rarely found
in the blood of cancer patients and enrichment is necessary for
sensitive CTC detection. Most CTC enrichment technologies
are anti-EpCAM antibody based even though CTC identification
criteria are cytokeratin positive (CK+), CD45 negative (CD45-)
and 4'6-diamidino-2-phenylindole (nuclear stain) positive
(DAPI+). However, some tumor cells express low or no EpCAM.
Here we present a highly sensitive and reproducible enrichment
method that is based on binding to anti-CK alone or a
combination of anti-CK and anti-EpCAM antibodies.
Methods Blood samples from 49 patients with metastatic
breast cancer were processed using the CellSearch™ system
(Veridex, LLC, Raritan, NJ, USA), in parallel with our CTC assay
method. We used anti-CK alone or in combination with anti-
EpCAM antibodies for CTC enrichment. Brightfield and
fluorescence labeled anti-CK, anti-CD45 and DAPI (nuclear
stain) images were used for CTC identification. The Ariol®
system (Genetix USA Inc, San Jose, CA, USA) was used for
automated cell image capture and analysis of CTCs on glass
slides.
Results Our method has the capability to enrich three types of
CTCs including CK+&EpCAM+, CK+&EpCAM-/low, and CK-/
low&EpCAM+ cells. In the blind method comparison, our anti-CK
antibody enrichment method showed a significantly higher CTC
positive rate (49% vs. 29%) and a larger dynamic CTC detected
range (1 to 571 vs. 1 to 270) than that of the CellSearch™
system in the total of 49 breast cancer patients. Our method
detected 15 to 111% more CTCs than the CellSearch™ method
in patients with higher CTC counts (>20 CTCs per 7.5 ml of
blood). The three fluorescent and brightfield images from the
Ariol® system reduced the number of false-positive CTC events
according to the established CTC criteria.
Conclusion Our data indicate that the tumor-specific
intracellular CK marker could be used for efficient CTC
enrichment. Enrichment with anti-CK alone or combined with
anti-EpCAM antibodies significantly enhances assay sensitivity.
The three fluorescent and brightfield superior images with the
Ariol® system reduced false-positive CTC events.
Introduction
Circulating tumor cells (CTCs) are detectable in most blood
samples from patients with metastatic cancer using different
technologies. CTCs are rare and need to be enriched from the
patients' blood sample for better detection [1,2]. CTC analysis
has been performed mostly in breast cancer, the second lead-
ing cause of cancer death in women in the US and the West-
ern world. Metastatic breast cancer occurs when tumor cells
grow unregulated and eventually lose the ability to adhere to
one another. Current models of metastasis support the idea
that detached cancer cells travel in the lymphatic system, usu-
ally in axilla and intercostal spaces of the sentinel nodes, and/Page 1 of 11
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develops and a new tumor grows.
Bone is the most common site of metastasis in patients with
breast cancer. Detecting tumor cells within bone marrow has
emerged as a marker of disease recurrence or survival in
breast cancer patients [3]. Braun et al. reported that 30% of
women with primary breast cancer have disseminated tumor
cells in their bone marrow. In a 10-year follow-up study, Braun
et al. were able to show that these patients had a significantly
decreased disease-free survival rate and overall survival rate
when compared with patients with no disseminated tumor
cells [4,5]. However, sampling of bone marrow is painful for
the patient and aspiration cannot be used routinely for breast
cancer monitoring.
Detection of CTCs in blood has obvious advantages as a non-
invasive sampling procedure and has better potential of being
a real-time biopsy of tumors because blood can be sampled
frequently. Recently, Meng et al. analyzed CTCs from the
blood of patients with newly diagnosed, advanced breast can-
cer and from patients with recurrent breast cancer by measur-
ing gene status in CTCs compared with cancer cells in the
primary tumor tissue [6]. It was concluded that individual tumor
cell analysis could provide important information for clinical tri-
als to test the correlations between gene status data obtained
from CTCs before treatment and the responses of patients to
various therapeutic regimens. This might lead to diagnostic
tests that could select the therapy most likely to be effective
for an individual patient. This could be an opportunity to evalu-
ate CTCs as potential non-invasive tools for improving selec-
tion of individualised therapy [7].
Today, numerous methods are available to analyze CTCs from
blood. Slide-based systems are the most commonly used. Tra-
ditionally, immunocytochemistry is combined with brightfield
microscopy to detect CTCs on microscope slides. In 1999, a
consortium of European laboratories participated in the first
multi-centre study with the objective of reaching a general con-
sensus on the criteria for defining a circulating epithelial cell as
a cancer cell [8]. Subsequently, many new methods were
developed that included improved immunomagnetic separa-
tion techniques. In addition, fluorescence-based assays
gained importance. A review by Fehm et al. gives a good sum-
mary of the currently available CTC enrichment methods using
slide-based detection assays [2].
CTCs are rarely found in the blood of cancer patients. There-
fore, relatively large volumes of blood have to be processed to
increase the sensitivity of the assay. Detection of CTCs with-
out target cell enrichment or depletion of unwanted cells is
challenging. Hsieh et al. described a high-speed scanning
device that allows detection of circulating tumor cells after
depletion of red blood cells [9]. However, a comparison to a
reference method has yet to prove its superior performance.
The well-studied CTC assays available today are based on
enrichment with anti-EpCAM antibodies and subsequent
detection with anti-cytokeratin (CK) [10,11]. The CellSearch™
system is one example of these assays; it is based on anti-
EpCAM enrichment and is currently the only instrument with
regulatory-approval that allows enumeration and characteriza-
tion of CTCs in blood.
In a study by Cristofanilli et al., 177 patients with metastatic
breast cancer were tested for the presence of CTCs using the
CellSearch™ system. The study concluded that detection of
CTCs before initiation of first-line therapy in patients with met-
astatic breast cancer is highly predictive of progression-free
survival and overall survival [12,13]. Riethdorf et al. validated
the CellSearch™ system in a multi-centre study and concluded
that the system allows the reliable detection of CTCs in blood
and is suitable for the routine assessment of metastatic breast
cancer patients in the clinical laboratory [14].
CK is a specific tumor cell marker and is one criterion for CTC
identification. Usually, anti-EpCAM antibody is used to enrich
CTCs and CK is used to identify the cells. The differential
expression of CK and EpCAM on the same cell will be the key
to ensure that no target cells are missed. Those tumor cells
that express CK but with low or no EpCAM, or vice versa [15-
19], may not be enriched by anti-EpCAM antibody. Here we
describe an improved anti-CK-based method for CTC enrich-
ment and detection from the peripheral blood of breast cancer
patients. Our method uses the same antibodies to enrich and
identify CTCs. To compensate for low or no expression of
EpCAM and CK, we also developed an assay with a combina-
tion of anti-CK and anti-EpCAM antibodies that allows the
enrichment of all types of CTCs including CK+&EpCAM+,
CK+&EpCAM-/low and CK-/low&EpCAM+ tumor cells. We devel-
oped a staining method that visualizes three fluorescent
labeled markers and brightfield cell morphology information for
CTC identification and successfully applied it to the Ariol®, an
automated image capture and analysis system that can com-
bine the three fluorescent and brightfield images on the same
cell simultaneously. The comparison results with the Cell-
Search™ system have proven that our method has higher sen-
sitivity, reproducibility and better accuracy.
Materials and methods
The breast cancer cell lines MCF-7 and SK-BR-3 (ATCC,
Rockville, MD, USA) were used for cell spiking experiments.
Blood samples from healthy donors were obtained from
Advanced Bioscience Resources, Inc. (Alameda, CA, USA).
The healthy donors were between 18 and 50 years of age, and
had no current or medical history of malignancy of epithelial
origin. They were required to understand and sign an informed
consent form that conforms to federal and institutional guide-
lines. Blood samples from breast cancer patients were
obtained from the University of Vermont. All the metastatic
breast cancer patients were over 18 years of age. All enrolledPage 2 of 11
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were enrolled using institutional review board-approved proto-
cols. Patients must have had radiological or histological evi-
dence of metastatic cancer with haemoglobin levels more than
10 gm% and haematocrit levels more than 30%. No patients
were excluded from this study because of prior medical
treatment.
Blood from each healthy donor was collected into EDTA tubes
(BD Biosciences, San Jose, CA, USA) or CellSave tubes
(Veridex, LLC, Raritan, NJ, USA). Blood samples were main-
tained at room temperature for different time intervals and
processed within a maximum of 72 hours after blood drawing.
For the methods comparison study, patient blood samples
were shipped from the University of Vermont to Genetix USA,
Inc. (San Jose, CA, USA) and Quest Diagnostics Nichols Insti-
tute respectively (Chantilly, VA, USA). Blood samples were
processed in parallel in the blind study. A 7.5 to 10 ml sample
of whole blood was transferred to a 50 ml Falcon tube (Corn-
ing, Lowell, MA, USA) and gently mixed with red blood cell
removal buffer (CTC Enrichment and Detection Kit, Genetix,
New Milton, UK). After approximately five to 10 minutes (when
the colour of the blood changed to a transparent cherry red),
cells were immediately centrifuged at 700 × g for 10 minutes
at room temperature using a Beckman GS-6 centrifuge with
GH-3.8 buckets. The cell pellet was carefully resuspended in
0.5 ml dilution buffer (Carcinoma Cell Enrichment and Detec-
tion Kit, Miltenyi Biotec, Bergisch Gladbach, Germany). Block-
ing, permeation and fixation reagents (CTC Enrichment and
Detection Kit, Genetix, New Milton, UK) and enrichment rea-
gents (Carcinoma Cell Enrichment and Detection Kit, Miltenyi
Biotec, Bergisch Gladbach, Germany) were added as
described in Genetix's instructions for the CTC Enrichment
and Detection kit.
Cells were incubated for 45 minutes at room temperature and
gently mixed every 10 minutes. Dilution buffer was added to
each tube to make up a total of 10 ml in each. The tubes were
centrifuged at 300 × g for 10 minutes at room temperature
and the cells were resuspended in 1 ml dilution buffer. Each
sample was carefully applied to the centre of one 0.5 ml dilu-
tion buffer equilibrated MS separation column (Miltenyi Biotec,
Bergisch Gladbach, Germany) attached to a MiniMACS or
OctoMACS separator (Miltenyi Biotec, Bergisch Gladbach,
Germany). After washing three times with 0.5 ml dilution
buffer, the columns were detached from the cell separator.
Target cells were eluted into a 5 ml tube with 1 ml dilution
buffer. Hettich cytospin chambers (Hettich, Germany) were
assembled and the eluted target cells were directly added into
the cytospin reservoirs using a funnel that creates cytospins
with a diameter of 8.7 mm. Target cells were deposited onto
Poly-Prep™ PLL (poly-L-lysine coated) glass slides (Sigma, St.
Louis, MO, USA) by centrifugation for three minutes at 800
rpm using a Hettich Universal 16 centrifuge (Hettich, Ger-
many). The supernatant was carefully removed using a fine-
tipped transfer pipette. The slides were centrifuged one more
time for one minute at 1000 rpm to remove any extra liquid.
The slides were taken out from cytospin and dried for 30 to 60
minutes at room temperature or 37°C using a slide warmer
(Fisher, Pittsburgh, PA, USA). Target cells were fixed in 100%
acetone (Sigma) at -20°C for 10 minutes. The slides were
dried at room temperature for 30 minutes.
A Shandon Cadenza Immuno Stainer (Thermo Scientific,
Waltham, MA, USA) was used for the target cell staining. The
glass slides with fixed target cells were assembled onto the
Immuno Stainer and washed with PBS buffer (Genetix, New
Milton, UK) twice for three minutes. The slides were incubated
for 30 minutes with Image iT FX signal enhancer (Invitrogen,
Carlsbad, CA, USA). Cells were stained by either direct or
indirect labeling antibodies. In the case of direct labeling, we
used a set of fluorescein isothiocyanate (FITC) conjugated
anti-mouse IgG1 antibodies recognising CK 8, 18 and 19
(CTC Enrichment and Detection Kit, Genetix, New Milton,
UK); haematopoietic cells were stained with a DyeLight 549
conjugated anti-mouse IgG1 antibody recognising CD45
(CTC Enrichment and Detection Kit, Genetix, New Milton, UK).
The specificity of the antibodies was tested by Western blot
analysis and/or immunohistochemistry staining with specific
tumor tissues.
The healthy donor's blood samples with no tumor cells were
used as negative controls. The blood samples containing
tumor cell were used as positive controls. The non-specific
binding blocking reagents were used in the CTC assays.
In the case of indirect labeling, the primary antibody cocktail
contained a mouse IgG2 anti-CK (CAM5.2, BD Biosciences,
San Jose, CA, USA) and a mouse IgG1 anti-CD45 antibody
(Lab Vision, Freemont, CA, USA). Slides were incubated for
30 minutes with directly labeled antibodies (anti-CK FITC, anti-
CD45 TexasRed) or incubated for 30 minutes with primary
antibodies (anti-CK and anti-CD45). They were subsequently
washed twice with PBS buffer, then incubated with the sec-
ondary antibodies (goat anti-mouse Alexa 488 IgG2a for CK,
goat anti-mouse Alexa 568 IgG1 for CD45; Invitrogen/Molec-
ular Probes, San Diego, CA, USA) for another 30 minutes.
After washing twice with PBS buffer, the slides were stained
with brightfield staining dye (CTC Enrichment and Detection
Kit, Genetix, New Milton, UK) to enable visualization of intact
cell morphology under white light exposure. The 4'6-diamid-
ino-2-phenylindole (DAPI) mounting medium (Vector Labora-
tories, Burlingame, CA, USA) was used for cell nuclei staining.
Image analysis was performed using the Ariol® system. Slides
of stained target cells had barcodes affixed to them and were
introduced into the system via the data entry application. The
Ariol® was configured for all scanning, image capture and
processing to be associated with the CTC assay. The cellPage 3 of 11
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TexasRed and DAPI fluorescence channels and in brightfield.
The images of CK-FITC-positive targets were captured and
presented in the image gallery. Only the cells with CK and
DAPI positive, and CD45 negative [10-15,20] were counted
as CTCs. Cells were further identified by brightfield images
that have smooth staining and a round shape to discriminate
from debris or cell fragments.
All analyzed data was reviewed and re-classified as appropri-
ate. A report included the selected cell images for the com-
bined fluorescence channels (composite view), an image for
each of the separate fluorescence channels and a brightfield
image.
The effect of blood storage temperature and addition of a cell
preservative on tumor cell stability was tested with tumor cell
(GFP or DsRed MCF-7, DAPI labeled MCF-7 or unlabelled
MCF-7 and SKBR-3) spiked blood samples. Samples were
either drawn into regular EDTA tubes (Becton Dickinson,
USA) or CellSave tubes that contain EDTA plus a cell preserv-
ative. Samples were tested immediately after blood draw or
stored either for 24, 48 or 72 hours at room temperature or
4°C until processing. In total, 60 samples were processed,
including 12 controls.
Our method was compared with the CellSearch™ system in a
blinded experiment (CTCs were analyzed separately accord-
ing to the criteria before knowing any results from Cell-
Search™) using blood samples from metastatic breast cancer
patients. The patients' blood samples were obtained from the
University of Vermont, and were drawn into two separate Cell-
Save™ blood collection tubes. One tube of the blood was
processed in our laboratory (Genetix, USA) in San Jose, CA;
another tube of blood was processed by Quest Diagnostics
Nichols Institute according to the CellSearch™ protocol the
day after blood drawing. In total, 49 patient samples were
tested using both methods. Fifty control samples from healthy
donors were tested as negative controls.
Results
Blood collection, enrichment assay sensitivity and 
reproducibility
EDTA and CellSave tubes were used for blood collection and
the spiked tumor cell recoveries were compared (Table 1).
EDTA and CellSave tubes both showed very reliable cell
recovery results at 4°C up to three days after blood collection,
with the EDTA tubes being slightly better than CellSave, but
with no significant difference. At room temperature, the Cell-
Save tube was clearly better than the EDTA tube. The cell
recovery from the CellSave tube was better than from the
EDTA tube after the blood sample was stored at room temper-
ature for more than one day. Table 2 shows the sensitivity and
reproducibility of our CTC assay method. On day 1, the mean
cell recovery rate was 74.9% (standard deviation [SD] =
6.0%, coefficient of variation [CV] = 8.1%); on day 2 the mean
cell recovery rate was 80.6% (SD = 8.2%, CV = 10.1%); and
finally on day 3, the mean cell recovery rate was 79.4% (SD =
9.8%, CV = 12.4%). There was no significant difference in the
day to day assay repeats. The mean cell recovery rate for 16
replicates processed on the three different days was 78.9%
(SD = 8.2%, CV = 10.4%) (Table 2).
CTC detection in metastatic breast cancer patients
A total of 49 blood samples from metastatic breast cancer
patients were tested with two CTC assay methods and the
numbers of CTC detected from individual patients are shown
in Table 3 (only shows the CTC-positive individuals either by
CellSearch™ or our CTC method). With our method, 49% (24
out of 49) of metastatic breast cancer patients had at least one
CTC in 7.5 ml blood. The CellSearch™ assay detected CTCs
in only 29% of patients (14 out of 49, three patients' assays
failed by Quest were counted as negative).
Our method had a significantly higher CTC detection rate than
the CellSearch™ system (p < 0.01) and a wider dynamic CTC
range (1 to 571 vs. 1 to 270). The number of patient samples
reaching Immunicon's (current Veridex LLC, USA) prognosti-
cally relevant cut-off level of 5 or more CTCs in 7.5 ml blood
with our method was slightly higher than with CellSearch™
(16% vs. 12%) but this was not significant (p = 0.396). The
percentage of samples with one to four CTCs in our method
was significantly higher than the CellSearch™ method (33%
vs. 16%, p < 0.01) (Table 4). In the patients with higher CTC
Table 1
Spiked MCF-7 cell recovery rates in EDTA and CellSave tubes
At 4°C At room temperature
0 to 4 hrs 24 hrs 48 hrs 72 hrs 0 to 4 hrs 24 hrs 48 hrs 72 hrs
EDTA tube 63 ± 2 75 ± 1 73 ± 5 69 ± 7 51 ± 17 37 ± 1 29 ± 12 9 ± 5
CellSave tube 75 ± 12 61 ± 22 57 ± 9 70 ± 10 71 ± 9 59 ± 15 49 ± 3 39 ± 13
Results shown as mean ± standard deviation.Page 4 of 11
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15% to 111% more CTCs than the CellSearch™ method at
the individual level. No CTCs were detected in the 50 normal
healthy donors (negative controls) with our method (data not
shown).
During the comparison study for our methods, we repeatedly
collected blood samples from the same patients (Figures 1
and 2). Patient 18 (Figure 1) was a 45-year-old female with
stage IV breast cancer, metastatic to bone and liver. At time
point A and two weeks before time point B, the patient
received two cycles of bevacizumab (Genentech, USA)/pacli-
taxel (Hospira, USA). Capecitabine (Roche, USA) chemother-
apy was initiated at the beginning of November 2006 and in
response the CTC count decreased to less than five CTCs
and was 0 at February 2007. The CellSearch™ assay detected
at time point B more than five CTCs. All other time points
resulted in 0 CTCs. In contrast, our CTC assay, tracked CTCs
from time point A over C, D, and E. We were not able to proc-
ess the blood sample at time point B with our assay due to
problems with the shipment of the sample.
Patient 68 (Figure 2) had stage IV breast cancer with exten-
sive metastatases to bone. Initially, the patient was treated
with tamoxifen (Generic), then weekly paclitaxel when the can-
cer progressed. The patient went through an incomplete
course of radiation therapy. Letrozole (Novartis, USA) was ini-
tiated in response to an increasing level of CA27.29 with good
response. However, CA27.29 levels increased again, which
were reflected in the CTC counts (time point E). Both the Cell-
Search™ method and our Ariol® CTC method were in con-
cordance with the number of CTCs detected at time points A
to E.
Figure 3 shows the imaging capability and quality of the Ariol®
system compared with the Cellsearch™ system. After deposi-
tion of enriched cells to microscope glass slides, cells were
stained with fluorescent dye labeled antibodies and haematox-
ylin. The slides were automatically scanned and imaged in
three fluorescent channels and brightfield with the Ariol®. We
counted the cell as a CTC only when it was CK+, DAPI+ and
CD45- [10-15,20] and with intact cellular morphology. Our
method detected CTCs in blood samples from the same or dif-
ferent breast cancer patients with various sizes, shapes and
CK expression levels (Figure 3(a)). In addition, the brightfield
image shows the cell's morphology, allowing discrimination
between intact cells and artifacts like debris or cell fragments
(Figures 3(b) and 3(c)) and reduced false-positive CTC events
in the assay. When the blood samples from the cancer
patients were compared, our method and image analysis sys-
tem could detect CTC clusters frequently and clearly show
them in the gallery of the target image captures (Figure 3(d)),
which the CellSearch™ system did not detect in this study. The
output report from Ariol® provides image information and data
such as signal intensity, cell location in 'England Finder' (EF)
co-ordinates and selected case information (Figure 3(e)). The
image output report from the CellSearch® system has three
fluorescence channels capability but no brightfield information
as shown in Figure 3(f).
Combination of anti-CK and anti-EpCAM antibodies for 
CTC enrichment
The CTC-enrichment efficiency of anti-CK alone and the com-
bination of anti-CK and anti-EpCAM antibodies was compared
using the same patient's blood samples. Figure 4(a) shows our
new strategy using a combination of microbeads coated with
anti-CK and anti-EpCAM antibodies to enrich CTCs from
Table 2
Spiked MCF-7 cell recovery rates after enrichment from blood
Day repeat Number of repeats Recovery (%) mean ± SD % CV
Day 1 3 74.9 ± 6.0 8.1
Day 2 5 80.6 ± 8.2 10.1
Day 3 8 79.9 ± 9.8 12.4
Total 16 78.9 ± 8.2 10.4
SD, standard deviation; CV, coefficient of variation.
Table 3
Method comparison for circulating tumor cell (CTC) detection from blood samples of breast cancer patients
Patient ID 22 76 77 37 39 60 16 45 53 56 52 47 17 48 54 59 74 35 46 14 19 18 78 68 64 20 21
CTC# 
(CellSearch™)
1 F* F* 0 0 0 2 0 0 2 3 7 0 0 0 1 1 2 0 4 12 0 F* 21 25 143 270
CTC # (Ariol®) 0 0 0 1 1 1 1 2 2 2 2 2 3 3 3 3 3 3 4 8 9 11 26 27 29 164 571
F* Assay failed by Quest CellSearch™Page 5 of 11
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an example of CTC enrichment with anti-EpCAM and detec-
tion with CK. Our current method uses anti-CK antibody-
based enrichment to enrich and detect all CK+ CTCs. Our new
strategy is to use a combination of anti-CK and anti-EpCAM
antibodies to enrich and detect all types of CTCs according to
the current CTCs criteria.
We looked at the CTC detection using anti-CK (our current
method) and anti-EpCAM enrichment (CellSearch™ method)
in a blind comparison study. Here we also compared the CTC
enrichment and detection using anti-CK alone and the combi-
nation of anti-CK and anti-EpCAM antibodies in blood sam-
ples from breast cancer patients. Figure 4 shows that in one
breast cancer patient, 25 CTCs were detected (all single
CTCs) in one tube of the blood using anti-CK microbeads and
30 CTCs were detected (28 single CTCs plus one two-CTC
cluster) in another tube of the same patient's blood using the
combination of anti-CK and anti-EpCAM antibodies
microbeads (Figures 4(a), (b), (c)). A 20% higher CTC detec-
tion rate was achieved with our new strategy.
By comparing the average CK intensity of the enriched CTCs,
the enrichment with the combination antibodies (anti-CK and
anti-EpCAM) showed not only a higher CTC count, but also
detected more CTCs with relatively low CK expression levels
(Figure 4(d)). This result confirmed the theory that the method
using a combination of antibodies (anti-CK and anti-EpCAM)
had the highest sensitivity, followed by anti-CK enrichment
and then anti-EpCAM enrichment.
Discussion
The three criteria for CTCs determination are considered to be
CK+, DAPI+ and CD45- [10-15,20]. CTCs are rare and heter-
ogeneous in blood. Many different methods have been devel-
oped to isolate CTCs from peripheral blood and disseminated
tumor cells from bone marrow [2,21,22]. Today, available
methodologies include density gradient centrifugation [23-
31], immunomagnetic cell enrichment [32-39] and/or deple-
tion [40-42], flow cytometry [43,44], filtration [45-47] and
more. Often, different methods are combined with each other,
such as density gradient centrifugation and immunomagnetic
cell enrichment and/or depletion.
The CellSearch™ is automated, uses standardized reagents
and was recently validated in a multi-centre study [14]. The
study was conducted at three independent laboratories to val-
idate the analytical performance of the system for clinical use
in patients with metastatic breast cancer. It was concluded
that the system enabled the reliable detection of CTCs in
blood to routinely assess metastatic breast cancer patients.
One of the limitations of the CellSearch™ system is the anti-
EpCAM antibody-based enrichment strategy. Several authors
reported the heterogeneous expression of EpCAM in mam-
mary carcinomas [15,19]; downregulation of EpCAM was
reported for disseminated tumor cells in bone marrow and
CTCs in peripheral blood [15,19,48].
Most other reported CTC enrichment methods are also based
on anti-EpCAM antibodies only, but the enriched CTCs are
identified by anti-CK antibodies [10-15,20]. The reason for
using anti-EpCAM antibodies to enrich CTCs is because
EpCAM is a cell-surface marker and has an advantage in the
Table 4
Circulating tumor cell (CTC) distribution
CTC # CellSearch™ Ariol®
0 35 (71%) 25 (51%*)
1 to 4 8 (16%) 16 (33%*)
≥ 5 6 (12%) 8 (16%)
Positive % 29 49*
* Significant difference (p < 0.01) with Z-test.
Figure 1
Tracking circulating tumor cell (CTC) counts from a metastatic breast cancer patient (ID# 18) in response to different therapies (Ariol® vs. CellSearch™)
cancer patient (ID# 18) in response to different therapies (Ariol® vs. 
CellSearch™).
Figure 2
Tracking circulating tumor cell (CTC) counts from a metastatic breast cancer patient (ID# 68) in response to different therapies (Ariol® vs. CellSearch™)
cancer patient (ID# 68) in response to different therapies (Ariol® vs. 
CellSearch™).Page 6 of 11
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expressed in all tumor cells [15,19], ideally, it would make
better sense to use the same antibodies to enrich and identify
CTCs. In the present study, we described an anti-CK anti-
body-based CTC enrichment method and successfully
applied it to CTC assays of patients' blood samples.
In the blind comparison study of our method compared with
the CellSearch™ method, we used the same CellSave blood
collection tubes, processed the same patients' blood samples
simultaneously in our laboratory with our method and in Quest
Laboratories with the CellSearch™ method. A higher positive
CTC detection rate and a larger CTC detectable dynamic
range were obtained from our method in the 49 breast cancer
patients. We found that in the patients with low CTC counts,
there was a good correlation between the two methods. How-
ever, there were also variations in which some patients were
CTC positive by our method but not by CellSearch™, or vice
versa. These variations may be a result of the low frequency of
CTCs or the heterogeneity of CK and EpCAM expression in
the CTCs, resulting in certain types of CTCs being missed by
one or the another enrichment methods. In the 49 patient sam-
ples with CTC counts in the range of one to four, our method
showed a significantly higher CTC detection rate (p < 0.01)
and a larger CTC detection range than that of the CellSearch™
method. These results suggest that anti-CK antibody-based
enrichment is more sensitive than anti-EpCAM antibody-based
enrichment.
The most interesting results were obtained from the patients
with higher CTC counts. In the patients with more than 20
CTCs, our anti-CK enrichment method showed a 15% to
Figure 3
Image analysis of circulating tumor cells (CTCs) detected in the blood of breast cancer patientsi l i t r l  ( s) detected in the blood of breast cancer patients. (a) CTCs detected in blood samples from the same 
or different breast cancer patients vary in size, shape and cytokeratin (CK) expression level. (b) 'Boxed' cells with confirmed CTCs; to be classified 
as a CTC, the cell should be positive for CK, negative for CD45, positive for nuclear staining and be identified as intact cell through the brightfield 
image. (c) Brightfield (BF) imaging shows cell morphology, allowing discrimination between cells and artifacts like dye debris or cell fragments. (d) 
Composite image of a CTC cluster from a metastatic breast cancer patient. (e) Ariol®'s output report format including image information and such 
data as the signal level intensity, cell location in 'England Finder' (EF) coordinates and selected case information. (f) Image output report from the 
CellSearch™ system.Page 7 of 11
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Search™ method consistently in all four available patients. In
other words, the anti-EpCAM antibody-based enrichment
method could lose a portion of the real CTCs population in
individual patients during the CTC assay process. The poten-
tial CTC loss by anti-EpCAM antibody-based enrichment
could be up to 52.7% when compared with anti-CK antibody-
based enrichment and could reduce the accuracy for patient
CTC monitoring. Similar results were reported in bone marrow
samples involving a total of 26 CK+ tumor cells, of which none
of them co-expressed EpCAM after chemotherapy. Most soft
tissue tumors and all lymphomas were EpCAM negative [15-
19,48]. More research is required to determine if those tumor
markers' expression changes are related to cell growth or
apoptosis [49]. In the case of CTCs that express low or no
EpCAM and low or no CK, we need different strategies to
enrich and target the correct cells.
CK is an intracellular protein. The biological mechanism of how
this protein can be used for cell enrichment is not entirely
understood. Our hypothesis is that the three reactions of cell
permeation, anti-CK antibody binding to CK antigens and cell
fixation are balanced in the same optimized reaction time
period. Anti-CK antibodies penetrate into the cell and bind to
CK inside the cell while the microbeads that are coupled to the
antibodies remain outside the cell. The cells are permeabilised
so anti-CK antibodies are able to bind to CK but not break the
cells that will be the key to success. Usually intracellular mark-
ers can be more specific; in addition, they can be used alone
or in combination with cell-surface markers for better cell
enrichment. Sometimes, cell-surface markers are not available
or may not be strong enough to enrich cells.
The key to the success of the current study lies with CK
enrichment with the intracellular marker that when utilized
alone showed equal or better sensitivity than surface-marker
EpCAM, which makes the enrichment strategy using combina-
tion antibodies meaningful. When the anti-CK antibodies are
added to the EpCAM enrichment process, it will be a plus
effect. Because CK and EpCAM are both heterogeneously
expressed on tumor cells (Figures 3 and 4(d)) [15,19,48], the
enrichment with the combined antibodies may increase the
sensitivity and reproducibility by the compensation effect of
biomarkers from each other. CTCs can be classified into three
classes: EpCAM+&CK-/low, EpCAM-/low&CK+ and
EpCAM+&CK+. CK-&EpCAM- tumor cells are not discussed in
this enrichment and detection study. None of the enrichment
methods reported have the capability to enrich all three types
of CTCs, either because of the enrichment antibody selection
or the identification antibody selection, which will cause
incomplete CTC profiling (the composition of different CTC
types) and CTC downstream analysis for individual patients
[6,16,29,35,50].
Figure 4
Circulating tumor cell (CTC) enrichment from blood of breast cancer patients using EpCAM and cytokeratin (CK) antibodies coupled to MACS microbeads
patients using EpCAM and cytokeratin (CK) antibodies coupled to 
MACS microbeads. (a) CTCs enrichment strategy for three types of 
CTCs. This will be the mode to enrich all CTCs theoretically. (b) Image 
gallery showing CTCs recovered after enrichment with anti-CK anti-
body only; (c) Image gallery showing the higher number of CTCs recov-
ered after enrichment with a combination of anti-CK and anti-EpCAM 
antibodies (the same blood sample as Figure 4(b)). (d) Plot showing 
CTC recovery rates after enrichment with anti-CK or a combination of 
anti-CK and anti-EpCAM in relationship to average cell anti-CK signal 
intensity.Page 8 of 11
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anti-CK and anti-EpCAM antibodies and can theoretically
enrich all the three types of CTCs by choosing the correct
markers for detection (Figure 4(a)). Our results indicate that a
higher CTC detection rate can be obtained by enriching with
anti-EpCAM and anti-CK in combination than with anti-CK
antibody alone. They also showed that the anti-EpCAM anti-
body may compensate for low CK expression, giving a better
sensitivity and reproducibility for CTC detection in the new
strategy (Figure 4(d)). Since most of the CTCs express both
CK and EpCAM [51], this new CTC-enrichment strategy will
consistently enrich most CTCs with CK+&EpCAM+, CK-/
low&EpCAM+ or CK+&EpCAM-/low. Therefore, this strategy may
allow enrichment of CTCs for further CTC profiling and down-
stream analysis and may also be beneficial for the isolation and
detection of CTC clusters (Figure 4(c)), which is another
advantage in the clinical application [23,24].
During the blind methods comparison study, we found some
events on the glass slide samples that meet the three CTC cri-
teria but it was clearly not a full cell by brightfield image analy-
sis. Reports using the CellSearch™ system describe a five
CTC threshold for prognostic relevance. It is not clear that the
presence of five CTCs has a clinical significance from 0 or one
to four CTCs, or if the threshold is due to the sensitivity and
accuracy of the CellSearch™ system. It is clear that no CTCs
were detected from the blood samples of most normal individ-
uals [10] and some CTCs are not easy to determine if the rely
only on the three fluorescence channels analysis. Our method
with the Ariol® system provides additional brightfield cell mor-
phological information that can reduce false-positive CTC
events (Figures 3(b), (c)); this may provide additional informa-
tion to understand the reasoning for the five CTC threshold for
prognostic relevance.
Most recently, Nagrath et al. described a microchip technol-
ogy that detected CTCs from almost 100% of patients with
various cancers [1]. It is a very exciting study result, but it does
not seem to solve the issue of missing the EpCAM-/low&CK+
CTCs because their microchip uses the anti-EpCAM anti-
body-based enrichment method. There is no data on a direct
comparison between the microchip technology and the Cell-
Search™ system, so it is not clear how much difference in sen-
sitivity it will make compared with the current Food and Drug
Administration cleared CellSearch™ system. To our knowl-
edge, our method with the Ariol® system is the first one to be
directly compared with the CellSearch™ system and yield
superior functionality in CTC enrichment and detection. The
strength of our system is a multiplex anti-CK/anti-EpCAM-
enrichment protocol combined with a fully automated image
analysis platform using both fluorescent and brightfield detec-
tion. This method has the capability to enrich all three types of
CTCs for complete CTC profiling and downstream analysis.
The advantages of our method are obvious: significantly higher
detection of heterogeneous CTCs, better image quality with
fluorescent and brightfield images, and better detection of
CTC clusters. A fully automated system with these advantages
may benefit CTC-related studies and further CTC downstream
analysis (fluorescence in situ hybridization, DNA/RNA etc)
[35,50,52-59].
Conclusion
The anti-CK antibody-based CTC-enrichment method uses an
intracellular CK protein marker to enrich CTCs and achieve
better sensitivity of CTC detection than that of the surface
EpCAM protein marker in blood samples from breast cancer
patients. The higher CTC detection in patients with high CTC
counts using our method compared with the CellSearch™ sys-
tem indicates the possible advantages of monitoring, diagnos-
tics and complete CTC profiling. With the combination of anti-
CK and anti-EpCAM antibodies, our method has the capability
to enrich and detect most types of CTCs, improving the sensi-
tivity and reproducibility for CTC enrichment and detection
and providing complete CTC profiling and downstream analy-
sis. Our method with the Ariol® system provides superior cell
image quality by combining fluorescent and brightfield images
that allow discrimination between intact cells and cell frag-
ments to reduce false-positive counts. The strategy of our
method can be used for enrichment of other cell types with
specific intracellular protein markers.
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